市場調査レポート
商品コード
1378760
コンパニオン診断市場レポート:製品・サービス、技術、適応症、エンドユーザー、地域別、2023-2028年Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
コンパニオン診断市場レポート:製品・サービス、技術、適応症、エンドユーザー、地域別、2023-2028年 |
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2~3営業日
|
世界のコンパニオン診断の市場規模は、2022年に59億米ドルに達しました。今後、IMARC Groupは、同市場が2028年までに133億米ドルに達し、2022年から2028年の間に14.5%の成長率(CAGR)を示すと予測しています。がんの有病率の増加、個別化医療に対する需要の急増、次世代シーケンシング(NGS)のような継続的な技術進歩は、市場を牽引する主な要因のいくつかです。
コンパニオン診断は、医師が最も効果的な治療計画を決定するのに役立つ医療検査です。これらの検査は、患者の組織や血液サンプルから特定のバイオマーカーを同定し、患者が特定の薬物や治療から恩恵を受ける可能性が高いかどうかを示すように設計されています。また、患者の詳細な生物学的プロファイルと作用機序(MOA)を分析し、医療専門家が薬の潜在的な副作用を理解するのを助けます。コンパニオン診断は、最適な治療計画を決定するために、遺伝子構成など、それぞれの患者固有の特徴を考慮するため、個別化医療において広く使用されています。これに加えて、がん患者の特定の遺伝子変異やC型肝炎患者のバイオマーカーを検査するために使用されることが増えています。これにより、医師は個々の患者に合わせた治療を行い、治療が成功する可能性を高め、副作用のリスクを減らすことができます。
世界中で様々な種類のがんが増加しており、より効果的で的を絞ったがん治療に対する需要が高まっています。コンパニオン診断は、特定のがん治療から利益を得る可能性が最も高い患者を特定するのに役立ち、その結果、患者の転帰を改善します。さらに、各患者の特性に合わせた個別化医薬品の需要が高まっていることも、同市場に有利な見通しをもたらしています。これと同時に、多くの感染症、心血管疾患、神経疾患、炎症性疾患の治療に標的薬や治療法が広く採用されていることも、もう一つの大きな成長促進要因として作用しています。これに加えて、コンパニオン診断に対する規制状況が良好で、米国食品医薬品局(FDA)などの規制当局から承認を受ける検査が増加していること、世界中で臨床試験の数が拡大していることも、市場の成長を強化しています。さらに、次世代シークエンシング(NGS)やリキッドバイオプシーの登場など、診断技術の進歩が進み、以前は検出が困難であったバイオマーカーの同定が可能になったことも、市場の成長に寄与しています。このほか、革新的なゲノム技術の開拓により、治療方針の決定に利用できる遺伝子変異やその他のバイオマーカーの同定が可能になったことも、市場の成長を後押ししています。その他にも、医薬品開発におけるバイオマーカー利用の増加、精密医療への広範な投資、コンパニオン診断の利点に関する消費者の意識の高まりなどが、市場に有益な成長機会をもたらしています。
The global companion diagnostics market size reached US$ 5.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.3 Billion by 2028, exhibiting a growth rate (CAGR) of 14.5% during 2022-2028. The increasing prevalence of cancer, the surging demand for personalized medicine, and ongoing technological advancements, such as next-generation sequencing (NGS), represent some of the key factors driving the market.
Companion diagnostics are medical tests that help physicians determine the most effective treatment plan. These tests are designed to identify specific biomarkers in a patient's tissue or blood sample, indicating whether the patient will likely benefit from a particular drug or therapy. They also analyze the detailed biological profile and the mechanism of action (MOA) of patients and assist medical professionals in understanding the potential side effects of medications. Companion diagnostics are widely used across personalized medicines as it considers each patient's unique characteristics, such as their genetic makeup, to determine the best treatment plan. In addition to this, they are increasingly used for testing specific genetic mutations in cancer patients or biomarkers in patients with hepatitis C. This helps physicians tailor treatments to individual patients, improving the likelihood of successful outcomes and reducing the risk of side effects.
The rising instances of various kinds of cancer across the globe are impelling the demand for more effective and targeted cancer treatments, which is primarily driving the market growth. Companion diagnostics help identify patients who are most likely to benefit from specific cancer therapies, resulting in better patient outcomes. Moreover, the growing demand for personalized medicines tailored to each patient's unique characteristics is creating a favorable outlook for the market. Concurrent with this, the widespread adoption of targeted drugs and therapies for treating numerous infectious, cardiovascular, neurological, and inflammatory conditions is acting as another significant growth-inducing factor. In addition to this, the favorable regulatory landscape for companion diagnostics, with an increasing number of tests receiving approval from governing authorities such as the United States Food and Drug Administration (US FDA), and the expanding number of clinical trials around the world are strengthening the market growth. Furthermore, ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, which have allowed identifying biomarkers that were formerly difficult to detect, are contributing to the market growth. Besides this, the development of innovative genomic technologies, which have enabled the identification of genetic mutations and other biomarkers that can be used to guide treatment decisions, is fueling the market growth. Other factors, such as the rising use of biomarkers in drug development, extensive investments in precision medicine, and the escalating consumer awareness regarding the benefits of companion diagnostics, are presenting remunerative growth opportunities for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global companion diagnostics market report, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product & service, technology, indication, and end user.
Assays, Kits and Reagents
Software and Services
The report has provided a detailed breakup and analysis of the companion diagnostics market based on the product & service. This includes assays, kits and reagents, and software and services. According to the report, assays, kits, and reagents represented the largest segment.
Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Others
A detailed breakup and analysis of the companion diagnostics market based on technology has also been provided in the report. This includes immunohistochemistry (IHC), polymerase chain reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), gene sequencing, and others. According to the report, polymerase chain reaction (PCR) accounted for the largest market share.
Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases
Others
The report has provided a detailed breakup and analysis of the companion diagnostics market based on the indication. This includes cancer (lung cancer, breast cancer, colorectal cancer, gastric cancer, melanoma, and others), neurological diseases, infectious diseases, cardiovascular diseases, and others. According to the report, cancer represented the largest segment.
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Others
A detailed breakup and analysis of the companion diagnostics market based on the end user has also been provided in the report. This includes pharmaceutical & biopharmaceutical companies, reference laboratories, contract research organizations, and others. According to the report, pharmaceutical & biopharmaceutical companies accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for companion diagnostics. Some of the factors driving the North America companion diagnostics market included the growing prevalence of cancer, the rising adoption of personalized medicines and targeted therapies, and significant advancements in next-generation sequencing (NGS).
The report has also provided a comprehensive analysis of the competitive landscape in the global companion diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Agilent Technologies, BioMerieux, Danaher Corporation, Roche Holding AG, Myriad Genetics Inc., Siemens Healthcare, and Thermo Fisher Scientific Inc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.